Spruce Biosciences is conducting two clinical trials evaluating its wholly-owned candidate, tildacerfont, a CRF1 receptor antagonist, for the treatment of adults with classic congenital adrenal hyperplasia (CAH). Spruce also plans to initiate a Phase 2 trial in pediatric classic CAH patients.

The CAHmelia clinical trials evaluating tildacerfont in adults with classic CAH are open for screening. To learn more, and see if you may qualify, please visit www.clarahealth.com/studies/cahmelia.

For more information on the ongoing trials in adult patients with classic CAH, please visit clinicaltrials.gov.